BYOMass Therapeutics � selective TGF-beta inhibitors

Founded by Dr. V. Margaret Jackson in ByoMassTx, short for ByoMass Therapeutics, is a preclinical pharmaceutical company developing novel biologic and small molecule drugs to modulate specific members of the TGF-β superfamily, for the treatment of orphan and common diseases of high unmet medical need.